Video
Dr. Narayan on efficacy, tolerability of nadofaragene firadenovec in BCG-unresponsive NMIBC
Author(s):
Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.
Video Player is loading.
Vikram M. Narayan, MD, highlights efficacy and safety data with the novel intravesical gene-mediated therapy nadofaragene firadenovec in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.
In a phase 3 trial nadofaragene firadenovec achieved a complete response (CR) rate of 53.4% at 3 months in a subgroup of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 disease. The 12-month CR rate was 24.3% and the median duration of CR was 9.69 months in these patients.
Related Videos
Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
John Taylor, III, MD, on novel options in NMIBC
Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG
What a long-term study of patients undergoing RARC reveals about upstaging
Sima Porten, MD, on the increased risk of bladder cancer among firefighters
Jason Hafron, MD, predicts coming advancements in bladder cancer
Related Content
